Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$3.86 - $8.01 $317,485 - $658,822
-82,250 Reduced 6.56%
1,172,250 $5.31 Million
Q1 2022

May 16, 2022

BUY
$7.01 - $10.94 $8.79 Million - $13.7 Million
1,254,500 New
1,254,500 $9.51 Million

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $345M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Tcg Crossover Management, LLC Portfolio

Follow Tcg Crossover Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tcg Crossover Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tcg Crossover Management, LLC with notifications on news.